Today, I talk about REGENXBIO and their in-house gene therapy candidates. Their most important asset in early clinical trials is RGX-314, indicated for wet AMD (and hopefuily Diabetic Retinopathy). This gene therapy could replace blockbuster drugs that treat millions patients, but is it a buy today? Follow me @matthewlepoire www.breakingbiotech.com this is not investment advice Support Breaking Biotech by donating to the tip jar: https://tips.pinecast.com/jar/breaking-biotech